Sign Out
Victoza is indicated for the treatment of adults, adolescents and children aged 10 years and above with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose-lowering medicinal products and/or insulin when these, together with diet and exercise, do not provide adequate glycaemic control (see Precautions and Pharmacology: Pharmacodynamics under Actions for available data on the different combinations).
Prevention of cardiovascular events: Victoza is indicated to reduce the risk of major adverse cardiovascular events (MACE), composed of cardiovascular (CV) death, non-fatal myocardial infarction and non-fatal stroke, in adults with type 2 diabetes who have established CV disease or are at high risk for CV disease.
